CRISPR for DuchenneGenome editing technology to correct the mutated dystrophin gene
The Duchenne Research Fund has awarded a £200,000 grant to the team at the Hospital for Sick Children in Toronto, Canada (‘Sick Kids’), who are working on using CRISPR/Cas9 technology to correct duplication mutations for Duchenne.
Sick Kids’ incoming President and CEO Dr Ronald Cohn has already had significant success as the first researcher to correct duplications in human cells in the lab, using CRISPR technology. Dr Cohn, Daria Wojtal and their team have since been working to achieve the same results in mice that have Duchenne duplications, and have so far seen exciting results.
The aim is to translate this into boys and young men with Duchenne in the future.
Although CRISPR has been widely used as a research tool, its potential in far-reaching therapeutic applications has largely been unexplored, explains Dr Cohn. “CRISPR is the most important technology that I have encountered in my scientific career thus far. Working with patients and families with genetic disorders, I’m often in a position where I can provide a diagnosis, and perhaps supportive care, but no treatment. CRISPR could change that. It could revolutionise the way we care for patients with currently untreatable genetic conditions.”
Duchenne muscular dystrophy is caused by a mutation in the dystrophin gene, which results in the absence of full-length dystrophin protein, needed to protect muscles. Without this protein, the muscles waste.
Current gene therapy clinical trials involve administering a ‘microdystrophin’ – a shortened form of the correct gene – with the aim of overriding the effect of the mutated gene. The dystrophin gene is the longest known gene in the body, and a full-length version is too large to deliver into the cells using existing drug delivery technology, so this shortened form is used.
However, recent advances in genome editing technologies based on CRISPR/Cas9 technology have the potential to correct the gene, returning it to the correct full-length version of the gene. Rather than ‘sending in’ a shortened version of the gene, this more recent approach aims to correct just the mutated part of the gene. In the case of patients whose mutation is a duplication (where a part of the genetic code is repeated twice) the CRISPR approach entails sending in ‘genetic scissors’ into the cells to ‘cut out’ the duplicated part of the gene, restoring the correct full-length dystrophin.
Check back here and in our news section in the coming months to find out how this project is progressing.
Funded in 2018-19
How does CRISPR differ from other treatment approaches?
The image below provides a visual representation of how CRISPR differs from treatments currently in use or being trialled for Duchenne.
Within our genes, DNA code (represented in the image by a cookbook), is transcribed into mRNA (akin to the reciting of a recipe). This then provides the information needed for the correct protein to be produced (the cake). When a mutation is present, this process is disrupted, and the protein is not produced adequately or at all. In the case of Exon Skipping, Stop Codon Readthrough and gene therapy treatment approaches for Duchenne, the result is a partial cake. As explained previously, in the case of gene therapy, this is due to the use of a shortened form of dystrophin. The CRISPR approach aims to produce the whole cake, thereby maximising the amount of protein produced.
Latest research news
Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne…
Solid Biosciences has issued an update on IGNITE DMD, the Phase I/II clinical study with its microdystrophin gene therapy, SGT-001.
The Duchenne Research Fund is pleased to share that the ground-breaking KineDMD activity monitoring study at Imperial College London/GOSH has been extended into 2021…
The Duchenne Research Fund has awarded a grant to Dr Barry Byrne and Dr Manuela Corti’s team at the University of Florida, whose vital work focuses on overcoming immunological challenges to ensure all boys and young men can benefit from gene therapy treatments for...
We are delighted to share the news that Dr Ronald Cohn, the head of the DRF’s Scientific Advisory Board, has been made President and CEO of the Hospital for Sick Children …
Solid Biosciences announces preliminary gene therapy clinical trial results and intention to dose escalate
Solid Biosciences has announced preliminary data from its gene therapy clinical trial, IGNITE DMD …
Learn more about what we fund.
Catch up on our fundraising and research progress.